echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Lancet: IL-17A/F Nanobody Solomizumab has been successfully treated in Phase II clinical trial of plaque psoriasis

    Lancet: IL-17A/F Nanobody Solomizumab has been successfully treated in Phase II clinical trial of plaque psoriasis

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The interleukin-17 family contains 6 subtypes, of which.


    Recently, researchers investigated the efficacy, safety and tolerability of solozumab in patients with plaque psoriasis.


    The research group was carried out in 41 medical institutions in Bulgaria, Canada, the Czech Republic, Germany, Hungary, Poland and the United States.


    313 patients participated in the study, including 52 people in the placebo group, 52 people in the solomizumab 30 mg group, 52 people in the solovizumab 60 mg group, 53 people in the solovizumab 120 mg normal load group, and solo There were 51 people in the Cizumab 120 mg enhanced load group and 53 people in the secukinumab 300 mg group.


    0 people (0%) in the placebo group, 25 people (48.


    Studies believe that the 30-120mg doses of solozumab all show good therapeutic effects for moderate to severe plaque psoriasis, which has the characteristics of rapid onset, long-lasting improvement, and better safety .


    Solocizumab 30-120mg doses all show good therapeutic effects for moderate to severe plaque psoriasis.


    Original source:

    Kim A Papp et al.


    IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.